Gary A Ulaner1, Alexandra M Zindman, Junting Zheng, Tae Won B Kim, John H Healey. 1. From the *Department of Radiology, Memorial Sloan Kettering Cancer Center, New York; †Department of Radiology, Weill Cornell Medical College, New York; ‡Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; §Department of Orthopaedics, Cooper University Hospital, Camden, NJ; ∥Department of Surgery, Memorial Sloan Kettering Cancer Center, New York; and ¶Department of Surgery, Weill Cornell Medical College, New York, NY.
Abstract
PURPOSE: Assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation to prevent pathological fractures. Better prediction of pathological fracture risk is needed. We evaluated if quantitative measures of FDG avidity can assess femoral pathological fracture risk in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act-compliant retrospective case-control study was performed under institutional review board waiver. Patients with MBC who received an FDG PET/CT from January 2008 to December 2014 and had pathological fracture of the proximal femur within 3 months of PET/CT were selected as cases. Patients with MBC who had an FDG PET/CT in 2013 were sequentially screened in reverse chronological order to identify patients with proximal femoral metastases on PET/CT but no subsequent pathological fracture to serve as a control group. The prespecified goal was to have twice the number of controls as cases. Target lesions in the proximal femur, from femoral head to 5 cm below the lesser trochanter, were analyzed on FDG PET/CT for SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis. Wilcoxon rank sum test was used to compare continuous variables in cases and controls. A nonparametric receiver operating characteristic analysis was performed to assess the ability of quantitative FDG measurements to differentiate between cases and controls. RESULTS: In 27 cases with pathological fracture and 55 controls without pathological fracture, all 4 quantitative measures of FDG avidity were statistically different between cases and controls (P < 0.001). A total lesion glycolysis of 81 could differentiate between fracture and nonfracture patients with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. CONCLUSIONS: Quantitative measures of FDG avidity may help identify breast cancer patients at high risk of subsequent pathological fracture of the proximal femur.
PURPOSE: Assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation to prevent pathological fractures. Better prediction of pathological fracture risk is needed. We evaluated if quantitative measures of FDG avidity can assess femoral pathological fracture risk in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: A Health Insurance Portability and Accountability Act-compliant retrospective case-control study was performed under institutional review board waiver. Patients with MBC who received an FDG PET/CT from January 2008 to December 2014 and had pathological fracture of the proximal femur within 3 months of PET/CT were selected as cases. Patients with MBC who had an FDG PET/CT in 2013 were sequentially screened in reverse chronological order to identify patients with proximal femoral metastases on PET/CT but no subsequent pathological fracture to serve as a control group. The prespecified goal was to have twice the number of controls as cases. Target lesions in the proximal femur, from femoral head to 5 cm below the lesser trochanter, were analyzed on FDG PET/CT for SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis. Wilcoxon rank sum test was used to compare continuous variables in cases and controls. A nonparametric receiver operating characteristic analysis was performed to assess the ability of quantitative FDG measurements to differentiate between cases and controls. RESULTS: In 27 cases with pathological fracture and 55 controls without pathological fracture, all 4 quantitative measures of FDG avidity were statistically different between cases and controls (P < 0.001). A total lesion glycolysis of 81 could differentiate between fracture and nonfracture patients with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. CONCLUSIONS: Quantitative measures of FDG avidity may help identify breast cancerpatients at high risk of subsequent pathological fracture of the proximal femur.
Authors: Molly P Hogan; Debra A Goldman; Brittany Dashevsky; Christopher C Riedl; Mithat Gönen; Joseph R Osborne; Maxine Jochelson; Clifford Hudis; Monica Morrow; Gary A Ulaner Journal: J Nucl Med Date: 2015-08-20 Impact factor: 10.057
Authors: Patrick G Morris; Gary A Ulaner; Anne Eaton; Maurizio Fazio; Komal Jhaveri; Sujata Patil; Laura Evangelista; Joseph Y Park; Cristian Serna-Tamayo; Jane Howard; Steven Larson; Clifford A Hudis; Heather L McArthur; Maxine S Jochelson Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte Journal: J Bone Miner Res Date: 2013-10-01 Impact factor: 6.741
Authors: Timothy A Damron; Hannah Morgan; Dave Prakash; William Grant; Jesse Aronowitz; John Heiner Journal: Clin Orthop Relat Res Date: 2003-10 Impact factor: 4.176
Authors: Maire Ratasvuori; Rikard Wedin; Johnny Keller; Markus Nottrott; Olga Zaikova; Peter Bergh; Anders Kalen; Johan Nilsson; Halldor Jonsson; Minna Laitinen Journal: Surg Oncol Date: 2013-04-04 Impact factor: 3.279
Authors: Julie J Willeumier; Mustafa Kaynak; Peer van der Zwaal; Sven A G Meylaerts; Nina M C Mathijssen; Paul C Jutte; Panagiotis Tsagozis; Rikard Wedin; Michiel A J van de Sande; Marta Fiocco; P D Sander Dijkstra Journal: Clin Orthop Relat Res Date: 2018-09 Impact factor: 4.176